Kornimate/medical-research-clean huggingface dataset:
the effect of huashibaidu granule on community-acquired pneumonia in children

Conditions: Community-acquired Pneumonia

Summary: the primary purpose of this study is to assess the efficacy and safety of huashibaidu granule for the treatment of community-acquired pneumonia in children compared with placebo and to demonstrate the efficacy of huashibaidu granule in improving clinical symptoms, removing pathogens, and shortening clinical course.

subjects diagnosed as community-acquired pneumonia in children according to "guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version)" at shanghai children's medical center will be consecutively screened and eligible patients will be recruited. for each enrolled patient, basic information as well as basic medical condition will be collected by investigators. the subjects will be randomly assigned to the huashibaidu group and the placebo group. during the study, patients will receive huashibaidu granule or placebo two times a day for five consecutive days. both groups of patients will receive conventional western medical observation and symptomatic treatment, including empiric anti-infective therapy (antibiotics) and symptomatic treatment such as antipyretic, expectorant and asthmatic. do not use other traditional chinese medicines, proprietary chinese medicines, and antiviral drugs. expectorants other than ambroxol cannot be used. after enrollment, investigator will evaluate and score patients' clinical symptoms at day 0, 1, 2, 3, 4, 5. detection of biomarkers associated with infection, screening of pathogen and imaging examination will be conducted at day 0. and pharyngeal swab will be collected by investigator for tngs at day 0, 3, 5.

Eligibility criteria:
inclusion criteria: 1. han nationality. 2. diagnosed as community-associated pneumonia in children according to "guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version)". 3. the first dose was given \< 5 days from the onset of pneumonia (onset time is defined as the time of the first symptoms or signs of lower respiratory tract infection). 4. the guardian agrees to participate in the study and signs the informed consent form. exclusion criteria: 1. the subject has severe respiratory distress, cyanosis, consciousness disorder, refusal to eat or dehydration. 2. the subject has chronic respiratory diseases, airway malformations, congenital heart disease, immune system diseases and other serious underlying diseases other than asthma. 3. the subject has moderate to severe persistent asthma or is in the acute asthma exacerbation. 4. the subject with influenza virus, pertussis, tuberculosis, fungi, and parasitic infections. 5. the subject with alanine aminotransferase (alt) or aspartate aminotransferase (ast) 1.5 times higher than normal values in blood biochemical detection items, abnormal renal function, or troponin. 6. the subject with any other reason that investigators consider unsuitable to participate in this study.

Keywords: pediatric community-acquired pneumonia huashibaidu granule
pregnant and lactating individuals & newborns covid-19 vaccination prospective cohort study

Conditions: SARS-CoV2 Infection; Covid19; Vaccine Reaction; Pregnancy Related; Immunogenicity

Summary: the plan-v study is an ontario-based prospective, longitudinal study that will consist of extensive biosampling and detailed data collection from pregnant women/individuals, who have received the covid-19 vaccine during their pregnancy, and their infants across the antenatal, delivery and postpartum periods.

there is a pressing need for research to answer critical questions about the role of maternal vaccination for protection of the mother-infant dyad, to inform public health recommendations and to support evidence-based decision-making by canadian families and their care providers. the investigators' goal is to generate rapid, reliable evidence specific to the immunogenicity and safety of covid-19 vaccines in the pregnant population. the specific plan-v study objectives are: 1. to evaluate immunogenicity of covid-19 vaccines in pregnant women/individuals and the fetal/newborn immune response to maternal vaccination. 2. to evaluate safety of covid-19 vaccination in pregnant women/individuals based on obstetrical, fetal and newborn health outcomes. 3. to compare immune responses to covid-19 vaccination and natural covid-19 disease among pregnant women/individuals and their infants exposed in utero 4. to compare the immune responses to covid-19 vaccination between pregnant and non-pregnant women/individuals. plan-v is an ontario-based prospective, longitudinal study that will consist of extensive biosampling and detailed data collection from pregnant women/individuals and their infants across the prenatal, delivery and postpartum periods. with this approach, detailed participant profiles will be generated that will enable us to explore vaccine reactogenicity; vaccine-associated adverse events; frequency of obstetrical and fetal/newborn outcomes; and measures of infant health and well-being. the study will build on existing resources and expertise available through the covid-19 ontario pregnancy event (cope) network to establish a prospective, longitudinal cohort study of pregnant women/individuals, and their infants. the plan-v study will consist of pregnant women/individuals who are planning to receive a covid-19 vaccine(s) at any stage in pregnancy.

Eligibility criteria:
inclusion criteria: * women/individuals ≥ 16 years of age who are ≥7 0/7 weeks' gestation on the day of enrollment * capacity to provide informed consent and to comprehend and comply with the study requirements * planning to deliver at a participating site hospital * planning to receive or have previously received one-dose of a health canada approved covid-19 vaccine (any product, any number of doses) during the current pregnancy exclusion criteria: * cases with known major fetal concerns * women/individuals who are fully vaccinated against covid-19 * women/individuals who are pregnant due to surrogacy, or planning to give their child up for adoption * women/individuals with a non-viable pregnancy (e.g., ectopic)
gpiibiiia inhibitors in the rescue and resurcor networks at the acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: in patients with acute myocardial infarction who are managed in the prehospital setting, and who will treated with primary angioplasty, we evaluate the benefit of an early administration of tirofiban, a powerful gpiibiiia inhibitors. patients are randomised to early administration in the ambulance or administration in the cathlab. the primary endpoint is timi 2-3 flow in the first coronary opacification of the culprit artery.


Eligibility criteria:
inclusion criteria: * age \> 18 years * information given to the patient and consent obtained * thoracic pain or symptoms of infarction * symptoms \< 12 hours * st deviation identified by electrocardiography (ecg) in at least 2 contiguous leads * transfer time to angioplasty room evaluated by the coordinating doctor as less than 90 minutes (from ecg diagnosis to arrival in angioplasty room) exclusion criteria * physiological or pathological conditions not compatible with a revascularisation procedure (in the acute phase of myocardial infarction (mi) * administration of fibrinolytics or another antigpiibiiia in the previous seven days * contraindications to aspirin or tirofiban or heparin * diagnosed severe kidney failure (dialysis, creatinin \> 350µmol/l * pregnancy * time for transfer to the angioplasty room evaluated by coordinating doctor as more than 90 minutes * subject participating in another trial * subject with high hemorrhagic risk.

Keywords: acute myocardial infarction, gpiibiiia inhibitors, primary angioplasty, tirofiban
mesothelin/gpc3/gucy2c-car-t cells against cancers

Conditions: Pancreas Cancer; CAR-T Cell Therapy; Mesothelin; Solid Tumor, Adult

Summary: the second generation of mesothelin targeted car-t cells that secret a fusion protein of il21 and scfv against pd1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. clinical studies will be performed to test anti-cancer function of the car-t cells for immunotherapy of human cancer patients with mesothelin expressions. in this phase i study, the safety, tolerance, and preliminary efficacy of the mesothelin-car-t cell immunotherapy on human cancers will firstly be evaluated.

1. choose appropriate patients with advanced pancreatic cancer or other cancers, with written consent for this study; 2. perform biopsy to determine the expression of mesothelin of the tumors by western blotting or ihc; 3. collect blood from the patients and isolate mononuclear cells, activate the t cells and transfect the t cells with mesothelin targeting car, amplify the transfected t cells as needed, test the quality and killing activity of the car-t cells and then transfer them back the patients via systemic or local injections, and follow up closely to collect related results as required; 4. to enhance the killing capability, cotreatment the patients with pd1/pdl1/ctla4 antibodies may be applied; 5. evaluate the clinical results as needed.

Eligibility criteria:
inclusion criteria: 1. patients with advanced cancer that expresses mesothelin protein; 2. life expectancy \>12 weeks; 3. adequate heart, lung, liver, kidney, and blood function; 4. available autologous transduced t cells with greater than or equal to 20% expression of mesothelin-car determined by flow-cytometry and killing of mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. informed consent explained to, understood by and signed by patient/guardian. patient/guardian given copy of informed consent. - exclusion criteria: 1. had accepted gene therapy before; 2. severe virus infection such as hbv, hcv, hiv, et al; 3. known hiv positivity; 4. active infectious disease related to bacteria, virus,fungi,et al; 5. other severe diseases that the investigators consider not appropriate; 6. pregnant or lactating women; 7. systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); 8. other conditions that the investigators consider not appropriate. -

Keywords: pancreas cancer car-t mesothelin solid tumor
sirolimus, mycophenolate mofetil and bortezomib as graft-versus-host disease (gvhd) prophylaxis after reduced intensity conditioning (ric) hematopoietic stem cell transplantation

Conditions: Graft-vs-Host Disease

Summary: this trial will test the hypothesis that the combination of sirolimus, mycophenolate mofetil, and bortezomib will be effective in preventing both acute and chronic gvhd after reduced intensity allogeneic stem cell transplantation.

the combination of tacrolimus and methotrexate is standard therapy for prevention of gvhd, however, our recent experience has demonstrated that the substitution of sirolimus for methotrexate provides superior gvhd control with reduced transplant-related toxicity. one limitation to the use of calcineurin inhibitors in gvhd prevention is the disruption in treg function and proliferation. based on our evolving understanding of the role of treg in the development of chronic gvhd, we propose a gvhd prophylactic regimen that is effective in prevention of acute gvhd, but by virtue of the maintenance of treg activity may be able to prevent chronic gvhd. we hypothesize that the substitution of mycophenolate mofetil for tacrolimus as well as the addition of bortezomib may provide similar protection against acute gvhd and prevent chronic gvhd while minimizing renal toxicity after transplantation.

Eligibility criteria:
inclusion criteria: 1. patients with hematologic malignancies, who are at high risk of complications after conventional myeloablative transplantation 2. patients must have a 6/6 matched, related donor. matching at hla class ii will be based on pcr of sequence specific primers (ssp). among family member transplants, serologic matching at class i is sufficient 3. patient age greater than 18 4. performance status 0-2 5. life expectancy of \> 100 days without transplantation 6. written informed consent must be obtained in all cases from the patient exclusion criteria: 1. pregnancy 2. prior allogeneic stem cell transplantation from any donor 3. evidence of hiv infection or active hepatitis b or c infection 4. heart failure uncontrolled by medications 5. total bilirubin \> 2.0 mg/dl that is due to hepatocellular dysfunction 6. ast \> 90 7. cholesterol \> 300 mg/dl or triglycerides \> 400 mg/dl while adequately treated 8. uncontrolled bacterial, viral or fungal infection 9. requirement for voriconazole at the time of hospital admission

Keywords: gvhd stem cell transplantation sirolimus
pet-dect for staging and imaged based radiotherapy planning in lung cancer

Conditions: PET CT

Summary: the overall goal of this project is to investigate the diagnostic performance of integrated f-18 fluorodeoxyglucose-positron emission tomography (fdg-pet) and dual energy ct (dect) imaging in determining the thoracic nodal status of small-cell lung cancer (sclc) and non-small-cell lung cancer (nsclc), and its impact on target volume delineation for image guided radiation therapy (igrt) planning.


Eligibility criteria:
inclusion criteria: to be eligible for the study: (all answers must be "yes" for subject to be eligible.) 1. subject must have a suspected sclc or nsclc. 2. subject must be 18-90 years of age. 3. subject must have been referred for a clinically indicated pet-ct. 4. subject must provide written informed consent prior to any study-related procedures being performed. 5. subject must be willing to comply with all clinical study procedures. exclusion criteria: the presence of the following excludes subjects from the study: (all answers must be "no" for subject to be eligible.) 1. subject is a pregnant or nursing female. exclude the possibility of pregnancy: * by testing (serum or urine βhcg) within 24 hours before contrast agent administration, or * by surgical sterilization, or * post-menopausal, with minimum one (1) year history without menses. 2. subject has impaired renal function (egfr\<30 ml/min). 3. subject has an acute psychiatric disorder or is cognitively impaired. 4. subject is using or is dependent on substances of abuse. 5. subject is unwilling to comply with the requirements of the protocol. 6. subject has an allergy against iodinated contrast agents and cannot be premedicated. 7. subject is in acute unstable condition.

Keywords: pet ct
efficacy of capacitive-resistive therapy on the treatment of myofascial pain

Conditions: Myofascial Pain Syndrome of Neck

Summary: myofascial pain syndrome (mps) is a painful musculoskeletal condition affecting the individuals' daily life presenting with muscle spasm, referred pain patterns, stiffness, restricted range of motion caused by trigger points. capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves. currently, although this modality is used to treat various acute or chronic musculoskeletal disorders, there is no specific data about myofascial trigger points in the literature. the investigators aimed to evaluate the efficacy of capacitive-resistive diathermy on the myofascial trigger point of neck/upper trapezius muscle area compared with the sham intervention of capacitive-resistive diathermy. volunteers with active myofascial trigger points in the upper trapezius and neck were included the study after being examined by sports medicine specialists. exclusion criteria were fibromyalgia, discal hernia, radiculopathy, myelopathy, having received trigger point injection and physical therapy within the last 1 month, neck or back surgery, rheumatismal diseases, pregnancy. patients were randomly allocated into two groups. group 1 will be treated with capacitive resistive diathermy and exercise. group 2 will be treated with placebo (sham) capacitive-resistive diathermy and exercise for 10 sessions at intervals of 24-48 hours. visual analog scale (vas), neck disability index (ndi) score, cervical range of motion (crom), active trigger point numbers will be evaluated before and after treatment. the study was designed as a prospective, randomized, placebo-controlled double-blind trial. the study was approved by the istanbul faculty of medicine ethics committee. all participants were informed of the study and signed written informed consent.


Eligibility criteria:
inclusion criteria: * volunteers * active myofascial trigger points in the upper trapezius and neck exclusion criteria: * fibromyalgia * discal hernia * radiculopathy, myelopathy * having received trigger point injection and physical therapy within the last 1 month * neck or back surgery * rheumatismal diseases * pregnancy

Keywords: myofascial neck pain capacitive-resistive therapy
comparison of fast-absorbing sutures for mohs surgery

Conditions: Cicatrix

Summary: this study is being carried out to assess equivalence of scar outcome for two absorbable sutures used for wound closure on the face in dermatologic surgery: rapidly absorbable polyglactin 910 (vicrylrapide™) and fast-absorbing plain gut (5-0 fast). this is important because absorbable sutures are commonly used in mohs surgery for epidermal closure, yet there is no evidence indicating if any of the sutures above allow for a better cosmetic outcome (less erythema, edema, and scarring).

prospective randomized controlled split-scar observer-blinded study. after dermatologic surgery on the face, surgeons have a choice between using non-absorbable or absorbable sutures for skin closure. a dermatologic surgeon favoring absorbable sutures for wound closure will consider many factors in material selection, including ease of manipulation, cost, and absorption time. however, there have been no randomized trials comparing the most important measure: aesthetic/cosmetic outcome. study endpoint/outcome: use three validated scar assessment tools.

Eligibility criteria:
inclusion criteria: * patients who are over 18 years and are having mohs surgery on the face. exclusion criteria: * patients with surgical wounds less than 4cm in length * patients requiring full thickness skin grafts for reconstruction * patients who are unable to attend routine postoperative follow-up appointments * patients who are receiving radiation therapy after surgery.

Keywords: suture comparison
diagnostic evaluation of the tear film

Conditions: Dry Eye Syndromes

Summary: the objectives of this study are to assess for a difference between normal and dry eye subjects in tear film quality using a diagnostic interferometry device and to determine whether there are associations between tear film quality and dry eye symptoms and signs.


Eligibility criteria:
inclusion criteria: * adults 18 year of age or older * willing and able to comply with study exam procedure exclusion criteria: * eyelid abnormality or ocular surface condition affecting ability to visualize tear film * women who are pregnant or nursing * any of the following conditions within specified timeframe prior to study participation: 1. instillation of eye drops 2. contact lens wear 3. use of oil-based facial cosmetics 4. swimming in chlorinated pool 5. eye examination procedures that may affect the tear film 6. participation in another ophthalmic clinical trial
combination of remifentanil and flurbiprofen in sedation and analgesia for eswl of pancreatic stone

Conditions: Pancreatic Stone Disease

Summary: extracorporeal shock wave lithotripsy (eswl) of pancreatic stones has been described as an effective approach for stone drainage and pain relief, and general or epidural anesthesia has been reported for such procedure. single infusion of remifentanil has been described in eswl of urinary stones, but it has never been described in eswl of pancreatic stones. moreover, single infusion of remifentanil might induce several complications, such as postoperative nausea and vomiting. the investigators attended to investigated whether combination of flurbiprofen with remifentanil reduced remifentanil dose and attenuated the complications.


Eligibility criteria:
inclusion criteria: * aged 18-65 years * asa i-ii * eswl indication was met exclusion criteria: * patients with hypertension * patients compromised in cardiopulmonary function * patients undergoing eswl for the second or more times

Keywords: extracorporeal shock wave lithotripsy remifentanil flurbiprofen pancreatic stone
injectable collagen scaffold™ combined with huc-mscs transplantation for patients with decompensated cirrhosis

Conditions: Decompensated Cirrhosis

Summary: the purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with human umbilical cord-derived mesenchymal stem cells (huc-mscs) transplantation in patients with decompensated cirrhosis.


Eligibility criteria:
inclusion criteria: participants must meet all of the following criteria: 1. subjects who are decompensated cirrhosis of any cause. 2. subjects are repeated exacerbations despite treatment and hospitalized more than once within one year because of complications of cirrhosis, (e.g., massive ascites, spontaneous bacterial peritonitis, gastrointestinal bleeding or hepatic encephalopathy). 3. need intermittent plasma albumin and oral diuretics supplement. 4. serum albumin \ 30% (prothrombin time \<20 s), moderate or mild ascites, spontaneous bacterial peritonitis and hepatic encephalopathy have been cured, child-pugh score ≥7. 5. peripheral blood hemoglobin concentration\> 70g/l，platelet count \> 3 × 10\^9/l, hematocrit (hct) level\>0.25. 6. no gastrointestinal bleeding during the last one month before enrolment. 7. patient has no conditional to undergo orthotopic liver transplantation (olt). 8. willing to sign informed consent. exclusion criteria: participants cannot meet any of the following criteria: 1. the presence of hepatocellular carcinoma (hcc) or other malignant tumors. 2. complicated with gastrointestinal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome and acute exacerbation of infection. 3. presence of severe comorbid diseases (e.g., severe renal, respiratory, cardiac or blood disease). 4. pregnant or lactating women. 5. allergy to g-csf, contrast agents and anticoagulants. 6. alcoholism or drug abuse.
nitric oxide lung diffusing capacity in systemic sclerosis

Conditions: Systemic Sclerosis

Summary: to date, two devices to measure nitric oxide lung diffusing capacity (dlno) are commercially available in europe. previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy people (radtke et al. erj open res. 2021 sep 13;7(3)). the extent and magnitude of between-device differences in people with lung function impairment and ventilation inhomogeneities is unknown.

the aim of this project is to compare two commercially available devices that measure lung diffusing capacity for nitric oxide (dlno) in people with systemic sclerosis and proven interstitial lung disease. 1. "masterscreentm" (pft pro, jaeger, carefusion, hoechberg, germany 2. "hypair" ("ha", medisoft, dinant, belgium).

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of systemic sclerosis by american college of rheumatology/ european league against rheumatism (acr/eular1) criteria (≥ 9 points) * interstitial lung disease proven with high-resolution computed tomography (hrct) * written informed consent * age ≥ 18 years exclusion criteria: * unstable clinical condition affecting lung function testing (i.e., major hemoptoe/-tysis or pneumothorax within the last 3 months, acute respiratory tract infection in the past two weeks), others according to the assessment of the treating physician * pregnancy

Keywords: nitric oxide dlno